Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug

Arcus and partner Gilead halted the Phase 3 STAR-221 trial for untreated advanced gastric and esophageal cancers after an Independent Data Monitoring Committee recommended stopping for futility—an interim overall survival analysis showed domvanalimab plus zimberelimab and chemotherapy did not improve OS versus nivolumab plus chemotherapy; safety was comparable and the STAR-221 and Phase 2 EDGE‑Gastric studies will be discontinued while investigators transition patients and teams perform a detailed analysis. Management said it will reallocate R&D resources to casdatifan, a HIF‑2α inhibitor that has shown strong single‑agent activity in >120 late‑line ccRCC patients in ARC‑20 and has a series of data and potential Phase‑3 milestones slated through 2026, while continuing development of quemliclustat (PRISM‑1 results expected 2027) and several immunology small molecules; RCUS shares fell about 11.1% to $23.35 on the news.

Analysis

Arcus Biosciences and partner Gilead halted the Phase 3 STAR-221 study after the Independent Data Monitoring Committee recommended stopping for futility following an event-driven interim overall survival analysis; the domvanalimab plus zimberelimab and chemotherapy regimen did not improve OS versus nivolumab plus chemotherapy in untreated advanced gastric and esophageal cancers. The safety profile of the domvanalimab combination was reported as similar to the comparator with no new safety signals, but both STAR-221 and the Phase 2 EDGE-Gastric studies will be discontinued while Arcus and Gilead communicate next steps to investigators and perform a detailed analysis.

Management will reallocate R&D focus to casdatifan, a HIF-2α inhibitor that demonstrated strong single-agent activity in more than 120 late-line ccRCC patients in the ARC-20 study; Arcus retains global rights outside Japan and parts of Asia (optioned to Taiho in Oct 2025). The company published a milestone roadmap with additional ARC-20 monotherapy analyses (early 2026), more mature combination data and alignment with the ongoing Phase 3 PEAK-1 (mid-2026), a second-half 2026 go/no-go for Phase 3 eVOLVE-RCC02 and potential late-2026 registrational initiation.

The market reacted with an ~11.1% drop in RCUS to $23.35 at publication and sentiment turned moderately negative, reflecting the loss of a late-stage oncology asset and near-term valuation pressure. Key investor watchpoints are the company’s detailed IDMC analysis, the ARC-20 data cadence through 2026, PRISM-1 pancreatic trial readout expected in 2027, and whether casdatifan’s upcoming data validate a path to registrational trials; absent new safety issues, clinical rather than safety risk is now the primary uncertainty.

Key Decisions for Investors

• Reduce near-term exposure to RCUS or tighten position sizing following the STAR-221 futility stop and the ~11% share decline until Arcus releases the detailed IDMC analysis and management clarifies program and commercial impacts
• Monitor casdatifan catalysts closely — updated ARC-20 monotherapy PFS (early 2026), mid-2026 combination data and the second-half 2026 go/no-go for Phase 3 — and consider rebuilding exposure only if those data demonstrate reproducible, clinically meaningful benefits
• Avoid initiating material new long positions ahead of the PRISM-1 readout in 2027 and the late-2026 registrational decision point for casdatifan, and consider hedging existing RCUS exposure to limit downside if further development setbacks occur